Conclusions
AD dementia
In conclusion, no clinically meaningful changes from baseline in neuropsychological assessments were observed across a range of BI 425809 doses administered to patients with mild-to-moderate probable AD dementia. All treatments were generally well tolerated, and no new safety concerns were identified in the trial.